Karyopharm files Chapter 11 with $441.5 million debt
Law360 · · AI-summarised by FinFlash
Cancer drug developer Karyopharm Therapeutics filed for Chapter 11 protection on Monday in the Southern District of Texas, carrying $441.5 million of debt. A restructuring support agreement with lenders and noteholders provides for a merger with Ayrmid, parent of Gamida Cell, which will act as lead bidder in a court-supervised sale. The company has secured up to $55 million of debtor-in-possession financing and expects to close in early 2027.
So What?
Equity holders typically face heavy dilution or wipeout in such plans. Watch the sale process and treatment of shareholders in court filings.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.